Iambic Therapeutics closed an oversubscribed financing of over $100 million to accelerate its AI-discovered drug portfolio and platform work, citing new collaborations and clinical advances. The round drew participation from institutional and strategic investors, highlighting sustained venture interest in AI-driven biotech. Iambic plans to deploy the funds across clinical development and platform expansion, including partnerships for target programs and licensing opportunities. Company statements and investor filings emphasized recent clinic-ready molecules and near-term IND plans, while partners noted Iambic’s neural-protein models as differentiators in structure prediction and design. Investors and industry analysts said the raise underscores strong capital appetite for AI-enabled discovery companies that can translate models into clinic-ready assets.